SYNTHESIS AND INHIBITORY POTENCY OF PEPTIDES CORRESPONDING TO THE SUBUNIT-2 C-TERMINAL REGION OF HERPES-VIRUS RIBONUCLEOTIDE REDUCTASES

被引:31
作者
GAUDREAU, P [1 ]
PARADIS, H [1 ]
LANGELIER, Y [1 ]
BRAZEAU, P [1 ]
机构
[1] NOTRE DAME HOSP, INST CANC MONTREAL, MONTREAL H2L 4M1, QUEBEC, CANADA
关键词
D O I
10.1021/jm00164a040
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
H-Tyr329-Ala330-Gly331-Ala332-Val333-Va334-Asn335-Asp336-Leu337-OH, the C-terminal end of herpes simplex virus ribonucleotide reductase subunit 2 (HSV R2), specifically inhibits viral enzyme activity by interacting with subunit 1 (HSV R1). In a previous structure-activity study, we identified four sites on the nonapeptide where the inhibitory potency could be modulated: a minimum active core 333-337, a spacer segment 330-332, and the N- and C-termini. To further explore the structural features of HSV R2-(329-337) that are required to obtain a potent inhibition, a series of analogues comprising modifications in these four regions were synthesized by solid-phase methodology. Changes in the segment 333-337 of the molecule decreased the inhibitory potency by more than 2-fold, except for the Ile334substitution, which resulted in a 1.5-fold increase in potency. Replacement of Tyr329by other aromatic or aliphatic amino acids diminished the nonapeptide activity from 1.4-fold to 5.9-fold. The spacer segment contributed to enhance potency. Modification with amino acids that could induce conformational changes, such as Pro or D-Ala, generated compounds with a similar or lower activity, respectively. Amidation or amino acyl addition at the carboxylic end was detrimental while acylation of the N-terminus was generally beneficial for the inhibitory potency. Disubstitution in position 332 and 334 by Thr and lle, which are present in the C-terminal portion of varicella-zoster virus ribonucleotide reductase subunit 2, resulted in a peptide that is 4.0 times more potent than HSV R2-(329-337), while each monosubstitution alone generated peptides with 150% of the activity of HSV R2-(329-337) nonapeptide. These results indicate a synergistic effect of the disubstitution which confers to this analogue physicochemical properties enhancing its ability to interact with its R1 binding site. © 1990, American Chemical Society. All rights reserved.
引用
收藏
页码:723 / 730
页数:8
相关论文
共 28 条
[1]  
BODANSZSKY M, 1981, PEPTIDES, V1, pCH3
[2]   RIBONUCLEOTIDE REDUCTASE ENCODED BY HERPES-SIMPLEX VIRUS IS A DETERMINANT OF THE PATHOGENICITY OF THE VIRUS IN MICE AND A VALID ANTIVIRAL TARGET [J].
CAMERON, JM ;
MCDOUGALL, I ;
MARSDEN, HS ;
PRESTON, VG ;
RYAN, DM ;
SUBAKSHARPE, JH .
JOURNAL OF GENERAL VIROLOGY, 1988, 69 :2607-2612
[3]   IDENTIFICATION OF VIRAL POLYPEPTIDES INVOLVED IN PSEUDORABIES VIRUS RIBONUCLEOTIDE REDUCTASE-ACTIVITY [J].
COHEN, EA ;
PARADIS, H ;
GAUDREAU, P ;
BRAZEAU, P ;
LANGELIER, Y .
JOURNAL OF VIROLOGY, 1987, 61 (06) :2046-2049
[4]   HERPES-SIMPLEX VIRUS RIBONUCLEOTIDE REDUCTASE INDUCED IN INFECTED BHK-21/C13 CELLS - BIOCHEMICAL-EVIDENCE FOR THE EXISTENCE OF 2 NON-IDENTICAL SUBUNITS, H-1 AND H2 [J].
COHEN, EA ;
CHARRON, J ;
PERRET, J ;
LANGELIER, Y .
JOURNAL OF GENERAL VIROLOGY, 1985, 66 (APR) :733-745
[5]   SPECIFIC-INHIBITION OF HERPESVIRUS RIBONUCLEOTIDE REDUCTASE BY A NONAPEPTIDE DERIVED FROM THE CARBOXY TERMINUS OF SUBUNIT-2 [J].
COHEN, EA ;
GAUDREAU, P ;
BRAZEAU, P ;
LANGELIER, Y .
NATURE, 1986, 321 (6068) :441-443
[7]  
COHEN GH, 1974, J VIROL, V41, P893
[8]  
COHEN JC, 1977, P SOC EXP BIOL MED, V155, P395, DOI 10.3181/00379727-155-39815
[9]   THE COMPLETE DNA-SEQUENCE OF VARICELLA-ZOSTER VIRUS [J].
DAVISON, AJ ;
SCOTT, JE .
JOURNAL OF GENERAL VIROLOGY, 1986, 67 :1759-1816
[10]   SPECIFIC-INHIBITION OF HERPESVIRUS RIBONUCLEOTIDE REDUCTASE BY SYNTHETIC PEPTIDES [J].
DUTIA, BM ;
FRAME, MC ;
SUBAKSHARPE, JH ;
CLARK, WN ;
MARSDEN, HS .
NATURE, 1986, 321 (6068) :439-441